Quality of Life and its Determinants in Patients With Treated Acromegaly : A Cross-Sectional Nationwide Study in China
© The Author(s) 2020. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com..
CONTEXT: Quality of life (QoL) continues to be impaired in acromegaly after treatment.
OBJECTIVE: We conducted the first nationwide survey assessing QoL status among Chinese patients with treated acromegaly and explored correlations with clinical parameters, treatment modalities, and outcomes.
DESIGN: Cross-sectional study.
SETTING: Survey via Chinese Association of Patients with Acromegaly (CAPA) online platform.
PATIENTS: Treated patients from CAPA.
MAIN OUTCOME MEASURES: QoL was assessed using acromegaly QoL questionnaire (AcroQoL), 5-level EuroQoL five-dimensional questionnaire (EQ-5D-5L), and 12-item short-form health survey questionnaire (SF-12).
RESULTS: Complete, valid questionnaires from 327 patients (mean age: 39.2 years, 61.5% females) at a mean of 10 years after treatment were included. Biochemical control was satisfied in 52.9% of these patients. The controlled patients had significantly better QoL than the uncontrolled patients in all AcroQoL dimensions, most SF-12 dimensions, and pain/discomfort and anxiety/depression dimensions of the EQ-5D-5L. Patients with either controlled or uncontrolled acromegaly had significantly worse QoL than the age- and sex-adjusted population reference in most SF-12 dimensions except for physical functioning. More acromegaly-associated symptoms and comorbidities at follow-up were independent risk factors for decreased QoL across all questionnaires. Medical treatment, especially with somatostatin analogs (SSAs), and radiotherapy were predictors of worse QoL. Female patients had lower scores of physical-related QoL than male patients.
CONCLUSIONS: Our study suggests that biochemical control improved but did not normalize QoL in acromegaly. Numbers of symptoms and comorbidities at follow-up, sex, radiotherapy, and medical treatment with SSAs were factors determining QoL of patients with treated acromegaly.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:106 |
|---|---|
| Enthalten in: |
The Journal of clinical endocrinology and metabolism - 106(2021), 1 vom: 01. Jan., Seite 211-225 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Guo, Xiaopeng [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Acromegaly |
|---|
| Anmerkungen: |
Date Completed 03.09.2021 Date Revised 03.09.2021 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1210/clinem/dgaa750 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM316484644 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM316484644 | ||
| 003 | DE-627 | ||
| 005 | 20231225161201.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1210/clinem/dgaa750 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1054.xml |
| 035 | |a (DE-627)NLM316484644 | ||
| 035 | |a (NLM)33079177 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Guo, Xiaopeng |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Quality of Life and its Determinants in Patients With Treated Acromegaly |b A Cross-Sectional Nationwide Study in China |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.09.2021 | ||
| 500 | |a Date Revised 03.09.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2020. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com. | ||
| 520 | |a CONTEXT: Quality of life (QoL) continues to be impaired in acromegaly after treatment | ||
| 520 | |a OBJECTIVE: We conducted the first nationwide survey assessing QoL status among Chinese patients with treated acromegaly and explored correlations with clinical parameters, treatment modalities, and outcomes | ||
| 520 | |a DESIGN: Cross-sectional study | ||
| 520 | |a SETTING: Survey via Chinese Association of Patients with Acromegaly (CAPA) online platform | ||
| 520 | |a PATIENTS: Treated patients from CAPA | ||
| 520 | |a MAIN OUTCOME MEASURES: QoL was assessed using acromegaly QoL questionnaire (AcroQoL), 5-level EuroQoL five-dimensional questionnaire (EQ-5D-5L), and 12-item short-form health survey questionnaire (SF-12) | ||
| 520 | |a RESULTS: Complete, valid questionnaires from 327 patients (mean age: 39.2 years, 61.5% females) at a mean of 10 years after treatment were included. Biochemical control was satisfied in 52.9% of these patients. The controlled patients had significantly better QoL than the uncontrolled patients in all AcroQoL dimensions, most SF-12 dimensions, and pain/discomfort and anxiety/depression dimensions of the EQ-5D-5L. Patients with either controlled or uncontrolled acromegaly had significantly worse QoL than the age- and sex-adjusted population reference in most SF-12 dimensions except for physical functioning. More acromegaly-associated symptoms and comorbidities at follow-up were independent risk factors for decreased QoL across all questionnaires. Medical treatment, especially with somatostatin analogs (SSAs), and radiotherapy were predictors of worse QoL. Female patients had lower scores of physical-related QoL than male patients | ||
| 520 | |a CONCLUSIONS: Our study suggests that biochemical control improved but did not normalize QoL in acromegaly. Numbers of symptoms and comorbidities at follow-up, sex, radiotherapy, and medical treatment with SSAs were factors determining QoL of patients with treated acromegaly | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a acromegaly | |
| 650 | 4 | |a biochemical control | |
| 650 | 4 | |a female | |
| 650 | 4 | |a medical treatment | |
| 650 | 4 | |a quality of life | |
| 650 | 4 | |a radiotherapy | |
| 700 | 1 | |a Wang, Kailu |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Siyue |e verfasserin |4 aut | |
| 700 | 1 | |a Gao, Lu |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Zihao |e verfasserin |4 aut | |
| 700 | 1 | |a Zhu, Huijuan |e verfasserin |4 aut | |
| 700 | 1 | |a Xing, Bing |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Shuyang |e verfasserin |4 aut | |
| 700 | 1 | |a Dong, Dong |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of clinical endocrinology and metabolism |d 1945 |g 106(2021), 1 vom: 01. Jan., Seite 211-225 |w (DE-627)NLM00001821X |x 1945-7197 |7 nnns |
| 773 | 1 | 8 | |g volume:106 |g year:2021 |g number:1 |g day:01 |g month:01 |g pages:211-225 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1210/clinem/dgaa750 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 106 |j 2021 |e 1 |b 01 |c 01 |h 211-225 | ||